

## IVT's 2nd Annual QbD

---

Feb 19, 2013 1:04 pm PST



While bio/pharmaceutical companies have embraced the principals of QbD, many have experienced challenges with the complexities of design and implementation of a QbD system. A successful QbD system requires an effective integration of quality standards, business processes for product commercialization and a common vision across all organizational components involved with QbD.

QbD is becoming increasingly used across the industry as a framework for developing process and articulating process understanding to the regulatory community. This generation of a wealth of data in manufacturing associated with a process could be leveraged to improve the development process. Yet, it often is not, for a variety of reasons, despite the manifest opportunities for improving the efficiency of process design.

Employing QbD methodology in product development or applying the methodology retrospectively to already commercialized products is a business decision like any other; management needs to understand the cost, the return on investment and the risks.

### Making the Case For QbD in Your Organization

James P. Catania, Managing Consultant, **Tunnell Consulting**

### Designing an Effective QbD System

Gary Denney, Director, Product R&D Quality and Supply Chain Management, **Eli Lilly and Company**

### Science-Based Pharmaceutical Product DevelopmentThe Quality by Design Approach

Robert J. Serra, Co-founder/Principal Consultant, **QbD Auditing, Inc.**

### Opportunities for Quality by Design and the Advancement of Pharmaceutical Manufacturing

John Lepore, Ph.D., Senior Director, Chemical Process Development, **Merck & Co., Inc.**

### Implementing a QbD System Company-Wide

Eda Ross Montgomery, Ph.D., Senior Director, Quality: CMC and QbD, **Vertex Pharmaceuticals**

### Implementing a QbD Program To Make Process Validation A Lifestyle Rather than an Event

Justin Neway, Ph.D., Chief Science Officer, **Aegis Analytical Corp.**

A QbD Approach to Process Qualification of Post-approval Changes for Biotech Products

Tamas Blandl, Ph.D., Principal Scientist, Process Development, **Amgen Inc.**

Process Predictive Distributions and QbD

John J. Peterson, Ph.D., Director, Research Statistics Unit, **GlaxoSmithKline**

Bridging from R & D to Ops with Quality by Design (QbD)

Shailesh K. Singh, **Former Wyeth Pharmaceuticals**

Experimental Strategies for Implementing Quality by Design

Ronald D. Snee, Ph.D., President, **Snee Associates, LLC**

Managing a Global Regulatory Submission: The Saxagliptin QbD Regulatory Experience

Gerald DiDonato, Associate Director, Global Regulatory Sciences CMC, **Bristol-Myers Squibb**

Applying QbD Principles to Process Validation

Kevin J. Bittorf, Ph.D., Chemical Engineering, MBA, Process Engineer, Associate Director, Formulation Development, **Vertex Pharmaceuticals**

Implementation of Quality-by-Design (QbD) via a Comprehensive Quality System (ICH Q8, Q9 and Q10)

Bob Mehta, MSQA, MBA, B.S. (Chem), ASQ – CQA, CBA, CRE, CQE, CSSBB, CSQE, Senior Regulatory Compliance Manager, **Edwards Lifesciences**

Developing a Roadmap to Implement Quality by Design

Barry (Bir) Gujral, Ph.D., MBA, Associate Director, Quality Engineering, **Noven Pharmaceuticals, Inc.** and Peter Amanatides, Vice President, QA and QC, **Noven Pharmaceuticals, Inc.**

Building Data-Based Knowledge and Skills Needed to Implement Quality by Design

Ronald D. Snee, Ph.D., President, **Snee Associates, LLC**

Quality Risk Management and Risk-Based Decision Making

Socrates Kyritsis, Director, Oral Product Development Pharmaceutical Sciences, **Merck** and Suliman Chawdry, Principal Scientist, Oral Product Development Pharmaceutical Sciences, **Merck**

---

**Source URL:** <http://www.ivtnetwork.com/article/ivts-2nd-annual-qbd>